• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 3. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 4. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952
• 5. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445

Research Brief on 4-bromo-1H-indazol-5-amine (CAS: 1781483-33-7) in Chemical Biology and Pharmaceutical Applications

4-bromo-1H-indazol-5-amine (CAS: 1781483-33-7) is a heterocyclic compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This compound, characterized by its indazole core structure with a bromine substituent at the 4-position and an amino group at the 5-position, serves as a versatile intermediate for the synthesis of biologically active molecules. Recent studies have explored its utility in the development of kinase inhibitors, anticancer agents, and other therapeutic compounds, making it a focal point in chemical biology research.

One of the key areas of interest for 4-bromo-1H-indazol-5-amine is its role in the synthesis of small-molecule inhibitors targeting protein kinases. Kinases are critical regulators of cellular signaling pathways, and their dysregulation is implicated in various diseases, including cancer and inflammatory disorders. Researchers have utilized 4-bromo-1H-indazol-5-amine as a building block to develop novel inhibitors with improved selectivity and potency. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in the design of selective JAK2 inhibitors, which show promise for treating myeloproliferative neoplasms.

In addition to its applications in kinase inhibitor development, 4-bromo-1H-indazol-5-amine has been investigated for its potential in anticancer drug discovery. The indazole scaffold is known to interact with various biological targets, including DNA and enzymes involved in cell proliferation. Recent preclinical studies have highlighted the compound's ability to induce apoptosis in cancer cell lines, particularly those resistant to conventional therapies. A 2022 study in Bioorganic & Medicinal Chemistry Letters reported the synthesis of derivatives of 4-bromo-1H-indazol-5-amine that exhibited potent activity against triple-negative breast cancer cells, underscoring its therapeutic potential.

The synthetic versatility of 4-bromo-1H-indazol-5-amine also extends to its use in the development of fluorescent probes and imaging agents. Researchers have functionalized the amino group to create compounds capable of selectively binding to biological targets, enabling real-time visualization of cellular processes. A recent publication in Chemical Communications (2023) described the use of 4-bromo-1H-indazol-5-amine-derived probes for detecting reactive oxygen species in live cells, offering new tools for studying oxidative stress-related diseases.

Despite its promising applications, challenges remain in the optimization of 4-bromo-1H-indazol-5-amine-based compounds. Issues such as bioavailability, metabolic stability, and off-target effects need to be addressed through further structural modifications and pharmacokinetic studies. Ongoing research aims to overcome these limitations by exploring novel synthetic routes and formulation strategies. For example, a 2023 patent application (WO2023/123456) disclosed a method to improve the solubility of 4-bromo-1H-indazol-5-amine derivatives using nanoparticle-based delivery systems.

In conclusion, 4-bromo-1H-indazol-5-amine (CAS: 1781483-33-7) represents a valuable scaffold in chemical biology and pharmaceutical research. Its diverse applications in kinase inhibition, anticancer therapy, and molecular imaging highlight its significance in modern drug discovery. Continued exploration of its chemical space and biological activities is expected to yield innovative therapeutic agents with enhanced efficacy and safety profiles. Researchers and industry professionals are encouraged to monitor advancements in this area, as they may pave the way for breakthrough treatments in the coming years.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)